Related Companies

• Skyepharma

Related Indices

• FTSE All-Share
• FTSE Small Cap
• techMARK 100
• techMARK

Related Sectors

British Gas – Price Control 2011

Previous

Next

Fix your energy bills until 2011.

We guarantee you peace of mind for 3 years, with no price premium to pay.

Find out more today!

News for Spread Betters

Previous

Next

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here.

Unsecured Loans

Previous

Next

Lighten the load of all those repayments with a low rate unsecured loan. This month's selected offers:

1. A&L Personal Loans
2. Barclays Loans
3. Halifax Loans

AMEX Platinum

Previous

Next

Money back on your spendings? With American Express Platinum MoneyBack card, you can get

• 5% Money Back* during your first 3 months, then
• standard Money Back rate up to 1.5% with
• typical APR 18.9% variable

Why look further? Apply now!

Date: Tuesday 22 Jul 2008

LONDON (ShareCast) - Pharmaceutical firm SkyePharma said its development and marketing partner Mundipharma has reported positive results from two Phase III clinical studies for the European development programme for asthma treatment Flutiform.

“We are delighted that along with the three Phase III pivotal efficacy studies conducted for NDA submission, we now have two further Phase III studies for European regulatory submission that have met their primary endpoints,” said chief operating officer Ken Cunningham.

Earlier this month, SkyePharma said its third Phase III efficacy study evaluating Flutiform has met its primary endpoints.

• News Channel